Biotech entity
All 1 tracked stories fall under one category: pharma. Cipla is most often covered alongside Dr. Reddy's Laboratories, which appears in 1 of these 1 story. At 8, the average consequence score sits above the same-window beat average of 6.4.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Cipla is most often covered alongside Dr. Reddy's Laboratories, which appears in 1 of these 1 story. At 8, the average consequence score sits above the same-window beat average of 6.4. Each story carries 2 original sources on average, compared with 2.8 for the broader beat in this window. Cipla appears in 1 tracked Biotech story from March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Cipla. Shared-story counts are live from our verified record — not editorial picks.
Indian pharmaceutical giants are preparing to disrupt the high-cost obesity drug market by launching low-cost generic GLP-1 treatments. This move is set to democratize access to weight-loss therapies and challenge the current market duopoly held by Western manufacturers.
Cipla is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
